Neoadjuvant therapy of rectal cancer new treatment perspectives

Antonino De Paoli, Roberto Innocente, Angela Buonadonna, Giovanni Boz, Roberto Sigon, Vincenzo Canzonieri, Sergio Frustaci

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

During the past two decades, significant advances have been made in the management of patients with rectal cancer. A number of clinical studies have demonstrated the efficacy of preoperative chemoradiation therapy with 5-fluorouracil (5-FU)-based regimens in decreasing local recurrences and improving survival and the likelihood of sphincter preservation. Although 5-FU has been the standard drug used in combination with radiation therapy for many years, new effective drugs including capecitabine, raltitrexed, irinotecan and oxaliplatin have been recently investigated in combination with radiation therapy in the preoperative setting. In addition, novel targeted biological agents including epidermal growth factor receptor inhibitors and vascular endothelial growth factor inhibitors have been shown to enhance the antitumor effect of both radiation and chemotherapy and are currently being explored in initial clinical trials. In the present review we summarize the results of adjuvant therapy. In addition, we will discuss the recently reported phase I-II trials with new drug plus radiation combinations in the preoperative treatment of patients with rectal cancer.

Original languageEnglish
Pages (from-to)373-378
Number of pages6
JournalTumori
Volume90
Issue number4
Publication statusPublished - Jul 2004

Fingerprint

Neoadjuvant Therapy
Rectal Neoplasms
oxaliplatin
irinotecan
Fluorouracil
Radiotherapy
Pharmaceutical Preparations
Radiation Effects
Biological Factors
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Therapeutics
Clinical Trials
Radiation
Recurrence
Drug Therapy
Survival

Keywords

  • Combined modality therapy
  • Neoadjuvant therapy
  • Rectal cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

De Paoli, A., Innocente, R., Buonadonna, A., Boz, G., Sigon, R., Canzonieri, V., & Frustaci, S. (2004). Neoadjuvant therapy of rectal cancer new treatment perspectives. Tumori, 90(4), 373-378.

Neoadjuvant therapy of rectal cancer new treatment perspectives. / De Paoli, Antonino; Innocente, Roberto; Buonadonna, Angela; Boz, Giovanni; Sigon, Roberto; Canzonieri, Vincenzo; Frustaci, Sergio.

In: Tumori, Vol. 90, No. 4, 07.2004, p. 373-378.

Research output: Contribution to journalArticle

De Paoli, A, Innocente, R, Buonadonna, A, Boz, G, Sigon, R, Canzonieri, V & Frustaci, S 2004, 'Neoadjuvant therapy of rectal cancer new treatment perspectives', Tumori, vol. 90, no. 4, pp. 373-378.
De Paoli, Antonino ; Innocente, Roberto ; Buonadonna, Angela ; Boz, Giovanni ; Sigon, Roberto ; Canzonieri, Vincenzo ; Frustaci, Sergio. / Neoadjuvant therapy of rectal cancer new treatment perspectives. In: Tumori. 2004 ; Vol. 90, No. 4. pp. 373-378.
@article{b2d3275c6cff4b89ad9f9c1379915012,
title = "Neoadjuvant therapy of rectal cancer new treatment perspectives",
abstract = "During the past two decades, significant advances have been made in the management of patients with rectal cancer. A number of clinical studies have demonstrated the efficacy of preoperative chemoradiation therapy with 5-fluorouracil (5-FU)-based regimens in decreasing local recurrences and improving survival and the likelihood of sphincter preservation. Although 5-FU has been the standard drug used in combination with radiation therapy for many years, new effective drugs including capecitabine, raltitrexed, irinotecan and oxaliplatin have been recently investigated in combination with radiation therapy in the preoperative setting. In addition, novel targeted biological agents including epidermal growth factor receptor inhibitors and vascular endothelial growth factor inhibitors have been shown to enhance the antitumor effect of both radiation and chemotherapy and are currently being explored in initial clinical trials. In the present review we summarize the results of adjuvant therapy. In addition, we will discuss the recently reported phase I-II trials with new drug plus radiation combinations in the preoperative treatment of patients with rectal cancer.",
keywords = "Combined modality therapy, Neoadjuvant therapy, Rectal cancer",
author = "{De Paoli}, Antonino and Roberto Innocente and Angela Buonadonna and Giovanni Boz and Roberto Sigon and Vincenzo Canzonieri and Sergio Frustaci",
year = "2004",
month = "7",
language = "English",
volume = "90",
pages = "373--378",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant therapy of rectal cancer new treatment perspectives

AU - De Paoli, Antonino

AU - Innocente, Roberto

AU - Buonadonna, Angela

AU - Boz, Giovanni

AU - Sigon, Roberto

AU - Canzonieri, Vincenzo

AU - Frustaci, Sergio

PY - 2004/7

Y1 - 2004/7

N2 - During the past two decades, significant advances have been made in the management of patients with rectal cancer. A number of clinical studies have demonstrated the efficacy of preoperative chemoradiation therapy with 5-fluorouracil (5-FU)-based regimens in decreasing local recurrences and improving survival and the likelihood of sphincter preservation. Although 5-FU has been the standard drug used in combination with radiation therapy for many years, new effective drugs including capecitabine, raltitrexed, irinotecan and oxaliplatin have been recently investigated in combination with radiation therapy in the preoperative setting. In addition, novel targeted biological agents including epidermal growth factor receptor inhibitors and vascular endothelial growth factor inhibitors have been shown to enhance the antitumor effect of both radiation and chemotherapy and are currently being explored in initial clinical trials. In the present review we summarize the results of adjuvant therapy. In addition, we will discuss the recently reported phase I-II trials with new drug plus radiation combinations in the preoperative treatment of patients with rectal cancer.

AB - During the past two decades, significant advances have been made in the management of patients with rectal cancer. A number of clinical studies have demonstrated the efficacy of preoperative chemoradiation therapy with 5-fluorouracil (5-FU)-based regimens in decreasing local recurrences and improving survival and the likelihood of sphincter preservation. Although 5-FU has been the standard drug used in combination with radiation therapy for many years, new effective drugs including capecitabine, raltitrexed, irinotecan and oxaliplatin have been recently investigated in combination with radiation therapy in the preoperative setting. In addition, novel targeted biological agents including epidermal growth factor receptor inhibitors and vascular endothelial growth factor inhibitors have been shown to enhance the antitumor effect of both radiation and chemotherapy and are currently being explored in initial clinical trials. In the present review we summarize the results of adjuvant therapy. In addition, we will discuss the recently reported phase I-II trials with new drug plus radiation combinations in the preoperative treatment of patients with rectal cancer.

KW - Combined modality therapy

KW - Neoadjuvant therapy

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=4644275714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644275714&partnerID=8YFLogxK

M3 - Article

C2 - 15510978

AN - SCOPUS:4644275714

VL - 90

SP - 373

EP - 378

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -